Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIO 2020 Notebook: Conversations On Rebates, Racism, And Remote Working

Executive Summary

News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.

You may also be interested in...



Biopharmas Manage To Deal During Pandemic

M&A activity faces numerous hurdles during the COVID-19 pandemic but companies are finding different ways to negotiate, conduct due diligence and get deals completed, BIO 2020 speakers said.

AstraZeneca Gilead Merger Intriguing But Unlikely

The possible creation of a pharma giant worth around $230bn of two firms who are leading the industry’s efforts to combat COVID-19 has caught the imagination but the likelihood of a match is limited.

Coronavirus Update: Lilly Begins Clinical Trial Of Antibody Therapy

Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142332

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel